Nuclear Medicine Innovation1

[WP-28-8] Development of α-methylated 3-boronophenylalanine derivatives with improved LAT1/LAT2 selectivity for BNCT.

Fuko Hirano¹、Naoya Kondo¹、Yusuke Murata²、Aya Sudani²、Takashi Temma¹ (1.Osaka Medical and Pharmaceutical University、2.Stella Pharma Corporation Sakai R&D Center)